Taligen raises a whopping $65M

Talk about big VC deals. Aurora, CO-based Taligen Therapeutics said today that it's expecting to receive up to $65 million in Series B financing. Top-tier investors Alta Partners and Clarus Ventures led the round, with participation from existing investors, including Sanderling Ventures, Tango and High Country.

Taligen has two lead products. The first, TA106, is a Fab fragment of a monoclonal antibody which inhibits complement factor B. TA106 will be used as a local therapy of inflammatory diseases such as asthma and macular degeneration. Taligen is also developing compounds which are intended to deliver complement inhibitors such as Factor H to sites where complement activation is occurring and driving inflammation. Both programs are in the preclinical stages of development.

"The progress made since our original investment in 2005 now allows us to develop multiple products to control the alternative pathway of complement activation. With this additional funding, we expect to move into clinical development with all of our lead candidates," said Timothy Mills, PhD, Chairman of the Board of Taligen.

- here's the release on the round

ALSO: The top 20 biotech VC deals of 2007. Special Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.